<DOC>
	<DOC>NCT00616460</DOC>
	<brief_summary>To determine the safety/efficacy of Bivallirudin Vs unfractionated heparin (UFH) on top of dual antiplatelet therapy in patients with high tendency for bleeding during urgent and elective PCI.</brief_summary>
	<brief_title>ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<criteria>Inclusion criteria (any of the following): â‰¥75 years Creatinin clearance rate &lt; 60 ml per minute Anemia (Hb 911 mg%) Hypertension: BP &gt; 180/95 mmHg but less than 210/110 m Hg Diabetic Pts Steroid treated Pts Recent (within 6 weeks) non major surgery Pts with hematological disorders associated with tendency for bleeding like Thrombocytopenia (platelets 50000150000) included TTP; Exclusion criteria: Age &lt; 18 year Acute STEMI (Primary PCI)* Rescue angioplasty &lt;12h after lytic therapy* Active bleeding S.C LMWH &lt; 8 hours or UFH &lt; 4 hours before PCI Using IIb /IIIa as an upstream therapy before PCI PCI which will be involved with obligatory IIb /IIIa therapy: (thrombotic complication, occlusive dissection) INR&gt;1.5 on day of cathetrization Bolus of 600mg of Clopidogrel before PCI Current pregnancy or women in reproductive age without contraceptives Hypersensitivity to heparin or bivalirudin or its components *(possible using IIB/IIIA)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>